Exploring cervical screening without a speculum in women aged 50-64
| ISRCTN | ISRCTN69709352 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN69709352 |
| IRAS number | 228847 |
| Secondary identifying numbers | IRAS 228847 |
- Submission date
- 20/07/2020
- Registration date
- 04/08/2020
- Last edited
- 15/08/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Plain English summary of protocol
Background and study aims
HPV is the name of a very common group of viruses. They do not cause any problems in most people, but some types can cause genital warts or cancer.
Women aged over 65 account for almost half of all cervical cancer deaths, most are in women not adequately screened when aged 50-64. Smears can become uncomfortable after the menopause and this can put some women off coming for cervical screening. One of the main causes of discomfort is the speculum (the instrument used to hold the walls of the vagina open). It is now possible to do cervical screening by testing for the virus that causes cervical cancer; human papillomavirus (HPV). An advantage of HPV testing is that samples can be taken without a speculum. Women can even collect a sample themselves (self-testing). Unfortunately, over half of women who take a self-test worry about not taking a good sample. Another option is to do HPV testing on a sample taken by a clinician without a speculum (non-speculum). Women would have the reassurance of having a clinician take the sample but with much less discomfort. This has not been tried before.
This study will assess the test performance and acceptability of non-speculum clinician samples for HPV testing in women aged 50+.
Who can participate?
There are 2 parallel studies; (i) GP primary care - women aged 50 - 64 attending routine cervical screening (to assess if non-speculum clinician samples can correctly identify women without disease) and (ii) colposcopy - women aged 50+ being investigated for possible cervical disease (to assess if non-speculum clinician samples can correctly identify women with disease).
What does the study involve?
A non-speculum clinician sample will be collected followed by a speculum clinician sample (in the GP study the second sample will be the routine smear). HPV test results from non-speculum samples will be compared with results from speculum samples and routine screening tests. Women in the GP study will complete a short questionnaire asking them about their experiences with the test.
What are the possible benefits and risks of participating?
Benefits: No personal benefit by taking part in this study. However, women will be contributing to research that will help improve cervical screening in the future.
Risk: We do not anticipate any risks associated with taking part in this study. Vaginal samples are routinely collected in the NHS.
Where is the study run from?
King's College London (UK)
When is the study starting and how long is it expected to run for?
April 2017 to January 2019
Who is funding the study?
Cancer Research UK
Who is the main contact?
Jane Rigney, hpvstudy@kcl.ac.uk
Contact information
Scientific
Kings College London
Faculty of Life Sciences & Medicine
London
SE1 9RT
United Kingdom
| Phone | +44 (0)2078485494 |
|---|---|
| jane.rigney@kcl.ac.uk |
Study information
| Study design | Multi centre observational cross sectional study |
|---|---|
| Primary study design | Observational |
| Secondary study design | Cross sectional study |
| Study setting(s) | GP practice |
| Study type | Screening |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | A cross-sectional study to assess the test performance and acceptability of non-speculum HPV testing in older women |
| Study acronym | SHOW |
| Study objectives | The test performance and acceptability of non-speculum clinician samples for HPV testing in women aged 50+ is as good as routine cervical screening using a speculum. |
| Ethics approval(s) | Approved 03/08/2017, North East - Tyne & Wear South Research Ethics Committee (Jarrow Business Centre Room 001 Rolling Mill Road, Jarrow, NE32 3DT; UK; +44 (0)207 1048084; tyneandwearsouth.rec@hra.nhs.uk), ref: 17/NE/0268 |
| Health condition(s) or problem(s) studied | Human papillomavirus (HPV) |
| Intervention | Eligible women will be consented to allow the GP or nurse to take a non-speculum sample before their rotuine sample. Study samples will be collected using a flocked vaginal swab (this is like a long cotton bud). HPV testing will be performed by the Barts Health NHS Trust Cytology laboratory. Only anonymous data will be collected for the study. This will be provided by the laboratory. HPV test results from non-speculum samples will be compared with results from speculum samples and routine screening tests. Study HPV results will not be reported to women since they will not inform management (women will be managed according to their usual care under the NHS Cervical screening programme). An exception to this is women in the routine screening arm (GP sub-study) who test cytology negative/HPV positive. These women will be referred by their GP for colposcopy. Eligible women will be identified by the colposcopy administrative team and sent the study information (invitation letter, patient information leaflet and HPV information sheet) with their colposcopy appointment letter. At their colposcopy appointment written informed consent will be taken by the colposcopist or colposcopist nurse. Before the colposcopy examination, the colposcopist/colposcopist nurse will collect a vaginal sample without a speculum, followed by a sample with a speculum. Almost all of these women will be HPV positive, and many will have high-grade cervical disease. This will allow us to assess how good HPV testing on non-speculum clinician samples is at correctl identifying women with high-grade cervical disease. |
| Intervention type | Other |
| Primary outcome measure | Measured at a single time point: 1. “Sensitivity” as the proportion of non-speculum HPV positives among (i) speculum HPV positives and (ii) women with high-grade disease (CIN2+ on histology and/or moderate dyskaryosis or worse on cytology) 2. “Specificity” as the proportion of non-speculum HPV negatives among women attending routine screening who are not found to have high-grade disease who are speculum HPV negatives and cytology screen-negative women (normal/borderline/mild dyskaryosis on cytology) |
| Secondary outcome measures | There are no secondary outcome measures |
| Overall study start date | 03/04/2017 |
| Completion date | 31/01/2019 |
Eligibility
| Participant type(s) | Mixed |
|---|---|
| Age group | Adult |
| Sex | Female |
| Target number of participants | 250 |
| Total final enrolment | 298 |
| Key inclusion criteria | 1. Women aged 50 - 64 years attending routine cervical screening in GP primary care 2. Women aged ≥ 50 years attending colposcopy who are likely or known to be HPV positive (e.g. referred with a cytology result of moderate or worse or positive on HPV triage testing) |
| Key exclusion criteria | 1. Women unable to provide informed consent 2. Women whose command of English is not sufficient to obtain informed consent. |
| Date of first enrolment | 20/08/2017 |
| Date of final enrolment | 31/01/2019 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centres
Mile End Hospital Site
Bancroft Road
London
E1 4DG
United Kingdom
Shadwell
London
E1 1BU
United Kingdom
London
E2 6JA
United Kingdom
Leytonstone
London
E11 1NR
United Kingdom
Whitechapel
London
E1 1FR
United Kingdom
London
E13 8S
United Kingdom
William Pl
Bow
London
E3 5ED
United Kingdom
Walthamstow
London
E17 8PX
United Kingdom
Poplar
London
E14 6PG
United Kingdom
Hackney
London
E9 7TA
United Kingdom
Hackney Downs
London
N16 7UA
United Kingdom
Lower Clapton
London
E5 0DH
United Kingdom
Clapton
London
E5 0PQ
United Kingdom
London
E1 0LS
United Kingdom
Sponsor information
University/education
Faculty of Life Sciences & Medicine
London
SE1 9RT
England
United Kingdom
| Phone | +44 (0)2078485494 |
|---|---|
| reza.razavi@kcl.ac.uk | |
| Website | http://www.kcl.ac.uk/index.aspx |
"ROR" |
https://ror.org/0220mzb33 |
Funders
Funder type
Charity
Private sector organisation / Other non-profit organizations
- Alternative name(s)
- CR_UK, Cancer Research UK - London, CRUK
- Location
- United Kingdom
Results and Publications
| Intention to publish date | 01/12/2020 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| Publication and dissemination plan | Planned publication in a high-impact peer-reviewed journal. |
| IPD sharing plan | The current data sharing plans for this study are unknown and will be available at a later date. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol file | version 3.0 | 18/03/2019 | 15/08/2022 | No | No |
| HRA research summary | 28/06/2023 | No | No |
Additional files
Editorial Notes
15/08/2022: Protocol file uploaded.
20/07/2020: Trial’s existence confirmed by North East - Tyne & Wear South Research Ethics Committee.
